The efficacy and safety of IBI314 on delta and omicron variant of SARS-CoV-2: First-in-human evidence

Ling Sang,Bo Cheng,Yuheng Yu, Yin Xi,Yun Wang, Bingdong Fan, Jijie Li,Jingtao Dai,Guifen Gan,Shijun Tong, Bin Sun, Xiaojing Qi,Wenhua Liang, Jianxing He,Nanshan Zhong

JOURNAL OF INFECTION（2022）

引用 1|浏览8

暂无评分

摘要

•IBI314 has a satisfying potency in Delta and Omicron-infected patients.•IBI314 is generally well-tolerated, with no serious adverse events observed.•IBI314 is effective in any stage of COVID-19 cases.•The earlier use of IBI314 might lead to better efficacy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要